• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

淋巴结比率作为甲状腺髓样癌复发的预后因素的价值。

Value of lymph node ratio as a prognostic factor of recurrence in medullary thyroid cancer.

机构信息

Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.

Department of Thyroid and Breast Surgery, Binzhou Medical University Hospital, Binzhou, Shandong, China.

出版信息

PeerJ. 2023 Mar 13;11:e15025. doi: 10.7717/peerj.15025. eCollection 2023.

DOI:10.7717/peerj.15025
PMID:36935920
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10019331/
Abstract

BACKGROUND AND OBJECTIVES

The purpose of this study is to evaluate the relationship between lymph node status (the number of resected lymph nodes; the number of metastatic lymph nodes, LNM, and lymph node ratio, LNR) and biochemical recurrence, disease-free survival (DFS), as well as overall survival (OS) in medullary thyroid carcinoma (MTC).

METHODS

This study enrolled MTC patients at Tianjin Medical University Cancer Institute and Hospital between 2011 and 2019. We used Logistic regression analysis, Cox regression models and Kaplan-Meier test to identify risk factors influencing biochemical recurrence, DFS, and OS.

RESULTS

We identified 160 patients who satisfied the inclusion criteria from 2011 to 2019. We used ROC analysis to define the cut-off value of LNR with 0.24. Multifocality, preoperative calcitonin levels, pathologic N stage, resected lymph nodes, LNM, LNR, and the American Joint Committee on Cancer (AJCC) clinical stage were significant ( < 0.05) prognostic factors influencing biochemical cure. In univariable analyses, gross extrathyroidal extension, preoperative calcitonin levels, pathologic T classification, pathologic N stage, resected lymph nodes, LNM, LNR, AJCC clinical stage, and biochemical cure were significant ( < 0.05) factors of DFS. When the multivariable analysis was performed, LNR was identified as predictor of DFS (HR = 4.818, 95% CI [1.270-18.276]). Univariable Cox regression models reflected that tumor size, pathologic N stage, and LNR were predictor of OS. Furthermore, multivariable analysis manifested that LNR was predictor of OS (HR = 10.061, 95% CI [1.222-82.841]).

CONCLUSIONS

This study illustrated that LNR was independent prognostic factor of DFS and OS in MTC. In addition, LNR influenced biochemical cure. Further investigations are needed to determine the optimal cut-off value for predicting prognosis.

摘要

背景与目的

本研究旨在评估颈淋巴结状态(切除的淋巴结数量;转移淋巴结数量、淋巴结转移率和淋巴结比率)与髓样甲状腺癌(MTC)患者生化复发、无病生存(DFS)和总生存(OS)之间的关系。

方法

本研究纳入了 2011 年至 2019 年在天津医科大学肿瘤医院就诊的 MTC 患者。我们使用 Logistic 回归分析、Cox 回归模型和 Kaplan-Meier 检验来确定影响生化复发、DFS 和 OS 的危险因素。

结果

我们从 2011 年至 2019 年共纳入 160 名符合纳入标准的患者。我们使用 ROC 分析确定 LNR 的截断值为 0.24。多灶性、术前降钙素水平、病理 N 分期、切除的淋巴结、LNM、LNR 和美国癌症联合委员会(AJCC)临床分期是影响生化治愈的显著(<0.05)预后因素。在单变量分析中,大体甲状腺外侵犯、术前降钙素水平、病理 T 分类、病理 N 分期、切除的淋巴结、LNM、LNR、AJCC 临床分期和生化治愈是 DFS 的显著(<0.05)因素。当进行多变量分析时,LNR 是 DFS 的预测因素(HR=4.818,95%CI[1.270-18.276])。单变量 Cox 回归模型反映肿瘤大小、病理 N 分期和 LNR 是 OS 的预测因素。此外,多变量分析表明 LNR 是 OS 的预测因素(HR=10.061,95%CI[1.222-82.841])。

结论

本研究表明 LNR 是 MTC 患者 DFS 和 OS 的独立预后因素。此外,LNR 影响生化治愈。需要进一步的研究来确定预测预后的最佳截断值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/078f/10019331/e78e8e421ff2/peerj-11-15025-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/078f/10019331/b11779e04d94/peerj-11-15025-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/078f/10019331/aeddbebba1e5/peerj-11-15025-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/078f/10019331/e78e8e421ff2/peerj-11-15025-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/078f/10019331/b11779e04d94/peerj-11-15025-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/078f/10019331/aeddbebba1e5/peerj-11-15025-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/078f/10019331/e78e8e421ff2/peerj-11-15025-g003.jpg

相似文献

1
Value of lymph node ratio as a prognostic factor of recurrence in medullary thyroid cancer.淋巴结比率作为甲状腺髓样癌复发的预后因素的价值。
PeerJ. 2023 Mar 13;11:e15025. doi: 10.7717/peerj.15025. eCollection 2023.
2
The prognostic value of lymph node ratio in Medullary thyroid carcinoma: A multi-center study.淋巴结比率在甲状腺髓样癌中的预后价值:一项多中心研究。
Eur J Surg Oncol. 2020 Nov;46(11):2023-2028. doi: 10.1016/j.ejso.2020.04.016. Epub 2020 Apr 18.
3
[Risk factors of recurrence or metastasis in patients with medullary thyroid carcinoma].[甲状腺髓样癌患者复发或转移的危险因素]
Zhonghua Yi Xue Za Zhi. 2022 Dec 27;102(48):3849-3855. doi: 10.3760/cma.j.cn112137-20220610-01296.
4
Metastatic Lymph Node Ratio for Predicting Recurrence in Medullary Thyroid Cancer.用于预测甲状腺髓样癌复发的转移淋巴结比率
Cancers (Basel). 2021 Nov 21;13(22):5842. doi: 10.3390/cancers13225842.
5
A proposed grading scheme for predicting recurrence in medullary thyroid cancer based on the Ki67 index and metastatic lymph node ratio.一种基于 Ki67 指数和转移性淋巴结比率预测甲状腺髓样癌复发的分级方案。
Endocrine. 2023 Jul;81(1):107-115. doi: 10.1007/s12020-023-03328-4. Epub 2023 Feb 23.
6
Lymph Node Ratio as a Predictive Factor of Persistent/Recurrent Disease in Patients With Medullary Thyroid Cancer: A Single-Center Retrospective Study.淋巴结比率作为预测甲状腺髓样癌患者持续性/复发性疾病的预测因子:一项单中心回顾性研究。
Endocr Pract. 2024 Mar;30(3):194-199. doi: 10.1016/j.eprac.2023.11.009. Epub 2023 Nov 25.
7
Ratio of positive lymph nodes: The prognostic value in stage IV thyroid cancer.阳性淋巴结比例:IV期甲状腺癌的预后价值。
Oncotarget. 2017 Jun 7;8(45):79462-79468. doi: 10.18632/oncotarget.18402. eCollection 2017 Oct 3.
8
The prognostic value of lymph node ratio in survival of non-metastatic breast carcinoma patients.淋巴结比率对非转移性乳腺癌患者生存的预后价值。
Breast Cancer Res Treat. 2020 Dec;184(3):839-848. doi: 10.1007/s10549-020-05885-y. Epub 2020 Aug 27.
9
Predictive Value of the Number of Harvested Lymph Nodes and Cut-Off for Lymph Node Ratio in the Prognosis of Stage II and III Colorectal Cancer Patients.II期和III期结直肠癌患者预后中淋巴结收获数量及淋巴结比率临界值的预测价值
J Invest Surg. 2019 Jan;32(1):1-7. doi: 10.1080/08941939.2017.1369605. Epub 2017 Oct 3.
10
Predictive value of number of metastatic lymph nodes and lymph node ratio for prognosis of patients with FIGO 2018 stage IIICp cervical cancer: a multi-center retrospective study.FIGO 2018 分期 IIICp 期宫颈癌患者转移淋巴结数量和淋巴结比值对预后的预测价值:一项多中心回顾性研究。
BMC Cancer. 2024 Aug 13;24(1):1005. doi: 10.1186/s12885-024-12784-8.

引用本文的文献

1
Prognostic prediction and comparison of three staging programs for patients with advanced (T2-T4) esophageal squamous carcinoma after radical resection.根治性切除术后晚期(T2-T4)食管鳞癌患者三种分期方案的预后预测及比较
Front Oncol. 2024 Jun 27;14:1376527. doi: 10.3389/fonc.2024.1376527. eCollection 2024.
2
Time Kinetics and prognosis roles of calcitonin after surgery for medullary thyroid carcinoma.降钙素在甲状腺髓样癌手术后的时间动力学和预后作用。
World J Surg Oncol. 2024 May 6;22(1):121. doi: 10.1186/s12957-024-03397-3.

本文引用的文献

1
Metastatic Lymph Node Ratio for Predicting Recurrence in Medullary Thyroid Cancer.用于预测甲状腺髓样癌复发的转移淋巴结比率
Cancers (Basel). 2021 Nov 21;13(22):5842. doi: 10.3390/cancers13225842.
2
Nodal disease burden and outcome of medullary thyroid carcinoma.甲状腺髓样癌的淋巴结疾病负担和结局。
Head Neck. 2021 Feb;43(2):577-584. doi: 10.1002/hed.26511. Epub 2020 Oct 27.
3
The prognostic value of lymph node ratio in Medullary thyroid carcinoma: A multi-center study.淋巴结比率在甲状腺髓样癌中的预后价值:一项多中心研究。
Eur J Surg Oncol. 2020 Nov;46(11):2023-2028. doi: 10.1016/j.ejso.2020.04.016. Epub 2020 Apr 18.
4
Prognostic value of lymph node ratio in metastatic papillary thyroid carcinoma.转移性乳头状甲状腺癌中淋巴结比率的预后价值
J Laryngol Otol. 2018 Jan;132(1):8-13. doi: 10.1017/S0022215117002250. Epub 2017 Nov 10.
5
Ratio of positive lymph nodes: The prognostic value in stage IV thyroid cancer.阳性淋巴结比例:IV期甲状腺癌的预后价值。
Oncotarget. 2017 Jun 7;8(45):79462-79468. doi: 10.18632/oncotarget.18402. eCollection 2017 Oct 3.
6
Timing and extension of lymphadenectomy in medullary thyroid carcinoma: A case series from a single institution.甲状腺髓样癌淋巴结清扫术的时机和范围:单中心病例系列研究。
Int J Surg. 2017 May;41 Suppl 1:S70-S74. doi: 10.1016/j.ijsu.2017.04.026.
7
The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.第八版 AJCC 癌症分期手册:继续从基于人群的方法向更“个体化”的癌症分期方法构建桥梁。
CA Cancer J Clin. 2017 Mar;67(2):93-99. doi: 10.3322/caac.21388. Epub 2017 Jan 17.
8
Metastatic lymph node ratio can further stratify risk for mortality in medullary thyroid cancer patients: A population-based analysis.转移性淋巴结比率可进一步对甲状腺髓样癌患者的死亡风险进行分层:一项基于人群的分析。
Oncotarget. 2016 Oct 4;7(40):65937-65945. doi: 10.18632/oncotarget.11725.
9
Surgery for lymph node metastases of medullary thyroid carcinoma: A review.甲状腺髓样癌淋巴结转移的外科治疗:综述。
Cancer. 2016 Feb 1;122(3):358-66. doi: 10.1002/cncr.29761. Epub 2015 Nov 5.
10
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.美国甲状腺协会修订的甲状腺髓样癌管理指南。
Thyroid. 2015 Jun;25(6):567-610. doi: 10.1089/thy.2014.0335.